Search Discovery Platform Fueled by our proprietary drug discovery platform, we are committed to discovering, developing, and delivering important new medicines to make a difference in the lives of people with cancer. Leveraging our deep expertise in kinase biology, we design kinase inhibitors targeting the switch pocket region of the kinase with the goal of developing potentially transformative medicines. Through our patient-inspired approach, we seek to improve treatment outcomes. Image Our proprietary drug discovery switch-control kinase inhibitor platform Kinases play a crucial role in regulating cellular functions and the communication of cells with their environments. When dysregulated, kinases contribute to the development and progression of diseases including cancer, inflammatory and autoimmune diseases. Our kinase inhibitors interact at a molecular level that is distinct from other kinase inhibitors and are designed to generate higher and more durable rates of response. Using our switch-control kinase inhibitor platform, we have developed a diverse pipeline of differentiated, wholly-owned, orally administered drug candidates.⁽¹⁾ (1) Development and commercialization exclusive license with Zai Lab in Greater China for QINLOCK®. A science driven company that has rapidly gone from discovery to commercialization VIEW OUR PIPELINE 1 marketed product in the U.S. 2 clinical development programs 250+ employees committed to defeating cancer 1,200+ patients treated in our clinical studies How our switch-control kinase inhibitor platform works Kinases are molecular signaling proteins located within cells. Kinases direct the activity of other signaling proteins, including other kinases, to orchestrate the function of a variety of essential cellular processes. A molecular control known as the activation switch governs whether the kinase is in the inactive “off switch” or the active “on switch”; enabling a high-level control of cellular processes. The transformation of a kinase from an inactive to an activated state is dependent upon the interaction of the activation switch with an area called the switch pocket; a mechanism of activation that is common among kinases. By directly targeting the switch pocket, we design inhibitors to be broadly active against the target kinase. twitter linkedin CONTACT US Main navigation Discovery Platform Pipeline Ripretinib Vimseltinib DCC-3116 Preclinical Pipeline Expanded Access Our Medicine QINLOCK® (ripretinib) Who We Are Management Board of Directors Join Us Open Positions Footer Utility Contact Us Terms of Use Privacy Policy Recruiting Privacy Policy Web Accessibility Statement © 2021 Deciphera Pharmaceuticals, Inc. QINLOCK and the QINLOCK logo are registered trademarks of Deciphera Pharmaceuticals, LLC. Deciphera and the Deciphera logo are trademarks of Deciphera Pharmaceuticals, LLC.